KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Inventory (2016 - 2025)

Historic Inventory for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.8 billion.

  • Gilead Sciences' Inventory fell 449.44% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 449.44%. This contributed to the annual value of $1.7 billion for FY2024, which is 430.89% down from last year.
  • Per Gilead Sciences' latest filing, its Inventory stood at $1.8 billion for Q3 2025, which was down 449.44% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Gilead Sciences' Inventory ranged from a high of $2.0 billion in Q2 2024 and a low of $1.5 billion during Q3 2022
  • Over the past 5 years, Gilead Sciences' median Inventory value was $1.7 billion (recorded in 2024), while the average stood at $1.7 billion.
  • In the last 5 years, Gilead Sciences' Inventory skyrocketed by 8042.6% in 2021 and then plummeted by 1669.48% in 2022.
  • Gilead Sciences' Inventory (Quarter) stood at $1.6 billion in 2021, then fell by 6.86% to $1.5 billion in 2022, then rose by 18.58% to $1.8 billion in 2023, then fell by 4.31% to $1.7 billion in 2024, then grew by 4.39% to $1.8 billion in 2025.
  • Its Inventory stands at $1.8 billion for Q3 2025, versus $1.8 billion for Q2 2025 and $1.8 billion for Q1 2025.